蒽环类药物治疗与心肌细胞萎缩及心脏病临床前表现相关
研究对27例乳腺癌女性在蒽环类药物治疗前后行心脏磁共振检查,发现治疗后左室射血分数和左室质量指数下降、细胞外容积增加、细胞内水寿命缩短,心肌水肿在约146至231天达峰,左室心肌细胞质量下降与肌钙蛋白T峰值升高相关。
要点
- 蒽环类治疗后左室质量指数下降可能反映心肌细胞萎缩,而非仅间质纤维化或水肿。
- 细胞外容积升高可由心肌细胞萎缩等间质纤维化和水肿之外的机制引起。
- 左室心肌细胞质量丢失程度随蒽环类治疗后肌钙蛋白T峰值升高而增加。
核心结论
- 蒽环类治疗后左室质量下降可能源于心肌细胞萎缩,提示间质纤维化和水肿之外的机制也可升高细胞外容积;左室心肌细胞质量丢失随蒽环类治疗后肌钙蛋白T峰值升高而增加。
研究设计与样本
- 研究为自身前后对照研究,纳入27例乳腺癌女性(平均年龄51.8±8.9岁,平均体重指数26.9±3.6 kg/m2),在蒽环类治疗前及治疗后最多3次行心脏磁共振检查,治疗剂量为240 mg/m2。
关键影像表现/征象
- 基线时无延迟钆增强,平均细胞外容积为0.32±0.038,平均细胞内水寿命为169±69 ms。
- 蒽环类治疗后351至700天,平均左室射血分数下降12%至58±6%(p<0.001),平均左室质量指数下降19 g/m2至36±6 g/m2(p<0.001)。
- 蒽环类治疗后351至700天,平均细胞外容积增加0.037至0.36±0.04(p=0.004),平均细胞内水寿命缩短62 ms至119±54 ms(p=0.004)。
- 心肌水肿在约146至231天达峰(p<0.001)。
- 左室质量指数与细胞内水寿命相关(细胞内水寿命每增加100 ms,β=4.1±1.5 g/m2,p=0.007),但与细胞外容积无关。
诊断标准与关键数值
- 基线平均左室射血分数为69.4±3.6%,平均左室质量指数为51.4±8.0 g/m2,10年Framingham心血管事件风险中位数为5%。
- 心脏肌钙蛋白T基线平均为4.6±1.4 pg/ml,蒽环类治疗后显著升高(p<0.001)。
- 总左室心肌细胞质量按(1-细胞外容积)×左室质量估算,在心脏肌钙蛋白T峰值>10 pg/ml后下降更快。
- 10年心血管事件风险与蒽环类治疗效应之间未发现显著交互作用。
临床应用与阅片要点
- 心脏磁共振可用于观察蒽环类治疗后的早期心肌组织重塑,包括心肌水肿、细胞外容积和细胞内水寿命变化。
- 报告左室质量指数下降时,需结合细胞内水寿命和细胞外容积变化,考虑心肌细胞萎缩的可能。
- 左室心肌细胞质量丢失与蒽环类治疗后肌钙蛋白T峰值升高相关,可结合肌钙蛋白T峰值评估心肌损伤程度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The goal of this study was to demonstrate that cardiac magnetic resonance could reveal anthracycline-induced early tissue remodeling and its relation to cardiac dysfunction and left ventricular (LV) atrophy.
BACKGROUND: Serum biomarkers of cardiac dysfunction, although elevated after chemotherapy, lack specificity for the mechanism of myocardial tissue alterations.
METHODS: A total of 27 women with breast cancer (mean age 51.8 ± 8.9 years, mean body mass index 26.9 ± 3.6 kg/m2), underwent cardiac magnetic resonance before and up to 3 times after anthracycline therapy. Cardiac magnetic resonance variables were LV ejection fraction, normalized T2-weighted signal intensity for myocardial edema, extracellular volume (ECV), LV cardiomyocyte mass, intracellular water lifetime (τic; a marker of cardiomyocyte size), and late gadolinium enhancement.
RESULTS: At baseline, patients had a relatively low (10-year) Framingham cardiovascular event risk (median 5%), normal LV ejection fractions (mean 69.4 ± 3.6%), and normal LV mass index (51.4 ± 8.0 g/m2), a mean ECV of 0.32 ± 0.038, mean τic of 169 ± 69 ms, and no late gadolinium enhancement. At 351 to 700 days after anthracycline therapy (240 mg/m2), mean LV ejection fraction had declined by 12% to 58 ± 6% (p < 0.001) and mean LV mass index by 19 g/m2 to 36 ± 6 g/m2 (p < 0.001), and mean ECV had increased by 0.037 to 0.36 ± 0.04 (p = 0.004), while mean τic had decreased by 62 ms to 119 ± 54 ms (p = 0.004). Myocardial edema peaked at about 146 to 231 days (p < 0.001). LV mass index was associated with τic (β = 4.1 ± 1.5 g/m2 per 100-ms increase in τic, p = 0.007) but not with ECV. Cardiac troponin T (mean 4.6 ± 1.4 pg/ml at baseline) increased significantly after anthracycline treatment (p < 0.001). Total LV cardiomyocyte mass, estimated as: (1 - ECV) × LV mass, declined more rapidly after anthracycline therapy, with peak cardiac troponin T >10 pg/ml. There was no evidence for any significant interaction between 10-year cardiovascular event risk and the effect of anthracycline therapy.
CONCLUSIONS: A decrease in LV mass after anthracycline therapy may result from cardiomyocyte atrophy, demonstrating that mechanisms other than interstitial fibrosis and edema can raise ECV. The loss of LV cardiomyocyte mass increased with the degree of cardiomyocyte injury, assessed by peak cardiac troponin T after anthracycline treatment. (Doxorubicin-Associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients; NCT03000036).
引用
- Ferreira de Souza T, Quinaglia A C Silva T, Osorio Costa F, et al. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease. JACC Cardiovasc Imaging. 2018. PMID: 30092965. doi:10.1016/j.jcmg.2018.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。